Lista de obras -

A comparative study of European rare disease and orphan drug markets ⬇️

artículo científico publicado el 17 de junio de 2010

A multi-criteria decision approach for ranking unmet needs in healthcare

artículo científico publicado en 2018

A review of the literature on the economics of noncompliance. Room for methodological improvement ⬇️

artículo científico publicado el 1 de enero de 2002

A social preference valuations set for EQ-5D health states in Flanders, Belgium

artículo científico publicado en 2009

Acceptability and Perceived Benefits and Risks of Public and Patient Involvement in Health Care Policy: A Delphi Survey in Belgian Stakeholders

artículo científico

An evaluation of managed entry agreements in Belgium: A system with threats and (high) potential if properly applied

artículo científico publicado en 2020

An overview of critical decision-points in the medical product lifecycle: Where to include patient preference information in the decision-making process?

scientific article published on 30 July 2020

Analysis of the costs of dialysis and the effects of an incentive mechanism for low-cost dialysis modalities ⬇️

artículo científico publicado el 22 de marzo de 2013

Assessing cancer patients' quality of life and supportive care needs: Translation-revalidation of the CARES in Flemish and exhaustive evaluation of concurrent validity

artículo científico publicado en 2016

Balancing evidence and public opinion in health technology assessments: the case of leukoreduction

artículo científico publicado en 2006

Barriers and facilitators related to the implementation of surgical safety checklists: a systematic review of the qualitative evidence.

artículo científico

Belgian guidelines for economic evaluations: second edition

artículo científico

Belgian methodological guidelines for pharmacoeconomic evaluations: toward standardization of drug reimbursement requests

artículo científico publicado en 2008

Budget impact analysis of orphan drugs in Belgium: estimates from 2008 to 2013.

artículo científico publicado en 2010

Calculating an intervention's (cost-)effectiveness for the real-world target population: The potential of combining strengths of both RCTs and observational data ⬇️

artículo científico publicado el 16 de mayo de 2012

Comparative effectiveness research and measuring the level of pharmaceutical innovation in the EU

scientific article published on 01 January 2012

Comparison of three instruments assessing the quality of economic evaluations: a practical exercise on economic evaluations of the surgical treatment of obesity

artículo científico publicado en 2008

Cost-effectiveness evaluation of a quadrivalent human papillomavirus vaccine in Belgium

artículo científico publicado en 2009

Cost-effectiveness of human papillomavirus vaccination in Belgium: do not forget about cervical cancer screening

artículo científico publicado en 2009

Critical assessment of belgian reimbursement dossiers of orphan drugs

artículo científico publicado en 2011

Design, Conduct, and Use of Patient Preference Studies in the Medical Product Life Cycle: A Multi-Method Study

scientific article published on 03 December 2019

Developing an agency's position with respect to patient involvement in health technology assessment: the importance of the organizational culture

artículo científico publicado en 2020

Developing the HTA core model for the online environment

artículo científico publicado en 2014

EXPLORING VALUES OF HEALTH TECHNOLOGY ASSESSMENT AGENCIES USING REFLECTIVE MULTICRITERIA AND RARE DISEASE CASE.

artículo científico publicado en 2017

Economic evaluation of the use of point-of-care devices in patients with long term oral anticoagulation ⬇️

artículo científico publicado el 1 de octubre de 2012

Economic implications of non-compliance in health care

scientific article published on 01 June 2002

Endpoints for relative effectiveness assessment (REA) of pharmaceuticals

artículo científico publicado en 2014

European drug reimbursement systems' legitimacy: five-country comparison and policy tool

artículo científico publicado en 2012

Factors and Situations Affecting the Value of Patient Preference Studies: Semi-Structured Interviews in Europe and the US

scientific article published on 18 September 2019

Factors and situations influencing the value of patient preference studies along the medical product lifecycle: a literature review

artículo científico publicado en 2018

Gender and educational differences in the association between smoking and health-related quality of life in Belgium.

artículo científico publicado en 2017

Giving Patients' Preferences a Voice in Medical Treatment Life Cycle: The PREFER Public-Private Project

artículo científico publicado en 2017

Harmonization of ethics in health technology assessment: a revision of the Socratic approach

artículo científico publicado en 2014

Harmonizing HTA

artículo científico publicado en 2010

Health professionals' perceptions of health status after renal transplantation: a comparison with transplantation candidates' expectations

artículo científico publicado en 2003

History of health technology assessment in Belgium

artículo científico publicado en 2009

Infection prevention and control strategies in the era of limited resources and quality improvement: A perspective paper ⬇️

artículo científico publicado el 19 de agosto de 2013

Issues Surrounding Orphan Disease and Orphan Drug Policies in Europe

Making health continuous: implications of different methods on the measurement of inequality

artículo científico publicado en 2006

Measuring patient-reported outcomes in solid organ transplant recipients: an overview of instruments developed to date

artículo científico publicado en 2007

Methodology for calculating a country's need for positron emission tomography scanners

artículo científico publicado en 2008

Multicriteria Decision Analysis to Support Health Technology Assessment Agencies: Benefits, Limitations, and the Way Forward

scientific article published on 16 October 2019

Noncompliance with immunosuppressive regimen in organ transplantation: is it worth worrying about?

artículo científico publicado en 2005

Opportunities and challenges for the inclusion of patient preferences in the medical product life cycle: a systematic review

artículo científico publicado en 2019

Patient Preferences in the Medical Product Life Cycle: What do Stakeholders Think? Semi-Structured Qualitative Interviews in Europe and the USA

scientific article published on 01 October 2019

Pharmaceutical regulation in 15 European countries review

artículo científico publicado en 2016

Prevalence, consequences, and determinants of nonadherence in adult renal transplant patients: a literature review

artículo científico publicado en 2005

Re-scaling social preference data: implications for modelling

artículo científico publicado en 2004

Revealing and acknowledging value judgments in health technology assessment

artículo científico publicado en 2014

Similarities and differences between five European drug reimbursement systems ⬇️

artículo científico publicado el 19 de septiembre de 2012

Stimulating pharmaceutical innovation in the EU ⬇️

artículo científico publicado el 1 de junio de 2011

Testing the HTA core model: experiences from two pilot projects

artículo científico publicado en 2009

The construct and concurrent validity of the EQ-5D in a renal transplant population.

artículo científico publicado en 2004

The determinants of defensive medicine practices in Belgium

artículo científico publicado en 2016

The economic impact of using alfuzosin 10 mg once daily in the management of acute urinary retention in the UK: a 6-month analysis

artículo científico publicado en 2005

The economic implications of non-adherence after renal transplantation

scientific article published on 01 January 2004

The impact of no-fault compensation on health care expenditures: an empirical study of OECD countries

artículo científico publicado en 2014

Towards a New Framework for Addressing Structural Uncertainty in Health Technology Assessment Guidelines

artículo científico publicado en 2017

Using threshold values for cost per quality-adjusted life-year gained in healthcare decisions ⬇️

artículo científico publicado el 25 de enero de 2011

Valorising and creating access to innovative medicines in the European union

artículo científico publicado en 2011

Which quality of life measures fit your relative effectiveness assessment?

artículo científico

[Orphan diseases and orphan medicines: a Belgian and European study]

artículo científico publicado en 2009

Lista de obras de

A comparative study of European rare disease and orphan drug markets ⬇️

A multi-criteria decision approach for ranking unmet needs in healthcare

A review of the literature on the economics of noncompliance. Room for methodological improvement ⬇️

A social preference valuations set for EQ-5D health states in Flanders, Belgium

Acceptability and Perceived Benefits and Risks of Public and Patient Involvement in Health Care Policy: A Delphi Survey in Belgian Stakeholders

An evaluation of managed entry agreements in Belgium: A system with threats and (high) potential if properly applied

An overview of critical decision-points in the medical product lifecycle: Where to include patient preference information in the decision-making process?

Analysis of the costs of dialysis and the effects of an incentive mechanism for low-cost dialysis modalities ⬇️

Assessing cancer patients' quality of life and supportive care needs: Translation-revalidation of the CARES in Flemish and exhaustive evaluation of concurrent validity

Balancing evidence and public opinion in health technology assessments: the case of leukoreduction

Barriers and facilitators related to the implementation of surgical safety checklists: a systematic review of the qualitative evidence.

Belgian guidelines for economic evaluations: second edition

Belgian methodological guidelines for pharmacoeconomic evaluations: toward standardization of drug reimbursement requests

Budget impact analysis of orphan drugs in Belgium: estimates from 2008 to 2013.

Calculating an intervention's (cost-)effectiveness for the real-world target population: The potential of combining strengths of both RCTs and observational data ⬇️

Comparative effectiveness research and measuring the level of pharmaceutical innovation in the EU

Comparison of three instruments assessing the quality of economic evaluations: a practical exercise on economic evaluations of the surgical treatment of obesity

Cost-effectiveness evaluation of a quadrivalent human papillomavirus vaccine in Belgium

Cost-effectiveness of human papillomavirus vaccination in Belgium: do not forget about cervical cancer screening

Critical assessment of belgian reimbursement dossiers of orphan drugs

Design, Conduct, and Use of Patient Preference Studies in the Medical Product Life Cycle: A Multi-Method Study

Developing an agency's position with respect to patient involvement in health technology assessment: the importance of the organizational culture

Developing the HTA core model for the online environment

EXPLORING VALUES OF HEALTH TECHNOLOGY ASSESSMENT AGENCIES USING REFLECTIVE MULTICRITERIA AND RARE DISEASE CASE.

Economic evaluation of the use of point-of-care devices in patients with long term oral anticoagulation ⬇️

Economic implications of non-compliance in health care

Endpoints for relative effectiveness assessment (REA) of pharmaceuticals

European drug reimbursement systems' legitimacy: five-country comparison and policy tool

Factors and Situations Affecting the Value of Patient Preference Studies: Semi-Structured Interviews in Europe and the US

Factors and situations influencing the value of patient preference studies along the medical product lifecycle: a literature review

Gender and educational differences in the association between smoking and health-related quality of life in Belgium.

Giving Patients' Preferences a Voice in Medical Treatment Life Cycle: The PREFER Public-Private Project

Harmonization of ethics in health technology assessment: a revision of the Socratic approach

Harmonizing HTA

Health professionals' perceptions of health status after renal transplantation: a comparison with transplantation candidates' expectations

History of health technology assessment in Belgium

Infection prevention and control strategies in the era of limited resources and quality improvement: A perspective paper ⬇️

Issues Surrounding Orphan Disease and Orphan Drug Policies in Europe

Making health continuous: implications of different methods on the measurement of inequality

Measuring patient-reported outcomes in solid organ transplant recipients: an overview of instruments developed to date

Methodology for calculating a country's need for positron emission tomography scanners

Multicriteria Decision Analysis to Support Health Technology Assessment Agencies: Benefits, Limitations, and the Way Forward

Noncompliance with immunosuppressive regimen in organ transplantation: is it worth worrying about?

Opportunities and challenges for the inclusion of patient preferences in the medical product life cycle: a systematic review

Patient Preferences in the Medical Product Life Cycle: What do Stakeholders Think? Semi-Structured Qualitative Interviews in Europe and the USA

Pharmaceutical regulation in 15 European countries review

Prevalence, consequences, and determinants of nonadherence in adult renal transplant patients: a literature review

Re-scaling social preference data: implications for modelling

Revealing and acknowledging value judgments in health technology assessment

Similarities and differences between five European drug reimbursement systems ⬇️

Stimulating pharmaceutical innovation in the EU ⬇️

Testing the HTA core model: experiences from two pilot projects

The construct and concurrent validity of the EQ-5D in a renal transplant population.

The determinants of defensive medicine practices in Belgium

The economic impact of using alfuzosin 10 mg once daily in the management of acute urinary retention in the UK: a 6-month analysis

The economic implications of non-adherence after renal transplantation

The impact of no-fault compensation on health care expenditures: an empirical study of OECD countries

Towards a New Framework for Addressing Structural Uncertainty in Health Technology Assessment Guidelines

Using threshold values for cost per quality-adjusted life-year gained in healthcare decisions ⬇️

Valorising and creating access to innovative medicines in the European union

Which quality of life measures fit your relative effectiveness assessment?

[Orphan diseases and orphan medicines: a Belgian and European study]